Premium
Colorectal Cancer–Derived Foxp3 + IL‐17 + T Cells Suppress Tumour‐Specific CD8 + T Cells
Author(s) -
Ma C.,
Dong X.
Publication year - 2011
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2011.02539.x
Subject(s) - foxp3 , cytotoxic t cell , cd8 , interleukin 21 , cancer research , immune system , biology , t cell , flow cytometry , colorectal cancer , il 2 receptor , immunology , cancer , medicine , in vitro , biochemistry
Abstract The pathogenesis of cancer is remained to be further understood. This study aims to investigate the role of tumour‐derived Foxhead box P3 (Foxp3) + interleukin (IL)‐17 + T cells on suppressing tumour‐specific CD8 + T cells. Colorectal cancer (CRC) tissue was collected from surgically removed cancer tissue of 22 patients with CRC. Foxp3 + IL‐17 + T cells in cancer tissue were examined by flow cytometry. A set of cell markers and cytokines expressed by Foxp3 + IL‐17 + T cells were determined by immune staining. By coculture with isolated peripheral CD8 + T cells, the immune regulatory capacity of Foxp3 + IL‐17 + T cells was examined. The results showed that a number of Foxp3 + IL‐17 + T cells were found in CRC tissue (22.8 ± 2.6 cells/mm 2 tissue) that was significantly more than in non‐cancer colonic mucosa (5.6 ± 1.04 cells/mm 2 tissue). The Foxp3 + IL‐17 + cells also CD4 + , CCR6 + , transforming growth factor (TGF)‐beta + and IL‐6 + . The CD8 + T cells proliferated markedly after exposure to tumour protein in culture that was suppressed in the presence of CRC–derived Foxp3 + IL‐17 + T cells; the suppression was attenuated by pretreatment with anti‐IL‐17 antibody. We conclude that CRC–derived Foxp3 + IL‐17 + T cells have the ability to suppress tumour‐specific CD8 + T cells. This subset of T cells may be a novel therapeutic target in the treatment of CRC.